Onset and Early Behavioral Effects of Pharmacologically Different Antidepressants and Placebo in Depression
The DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.
Abstract
This study was aimed at resolving the time course of clinical action of antidepressants (ADs) and the type of early behavioral changes that precede recovery in treatment-responsive depressed patients. The first goal was to identify, during the first 2 weeks of treatment, the onset of clinical actions of the selective serotonin reuptake inhibitor (SSRI), paroxetine, and the selective noradrenergic reuptake inhibitor, desipramine (DMI). The second aim was to test the hypothesis that the two pharmacologic subtypes would induce different early behavioral changes in treatment-responsive patients. The design was a randomized, parallel group, placebo-controlled, double-blind study for 6 weeks of treatment following a 1-week washout period. The study utilized measures of the major behavioral components of the depressive disorder as well as overall severity. The results indicated that the onset of clinical actions of DMI ranged from 3 to 13 days, averaged 13 days for paroxetine, and was 16-42 days for placebo. Furthermore, as hypothesized, the different types of ADs initially impacted different behavioral aspects of the disorder. After 1 week of treatment, DMI produced greater reductions in motor retardation and depressed mood than did paroxetine and placebo, and this difference persisted at the second week of treatment. Early improvement in depressed mood-motor retardation differentiated patients who responded to DMI after 6 weeks of treatment from those that did not. Paroxetine initially reduced anxiety more in responders than in nonresponders, and by the second week, significantly improved depressed mood and distressed expression in responders to a greater extent. Depressed patients who responded to placebo showed no consistent early pattern of behavior improvement. Early drug-specific behavioral changes were highly predictive of ultimate clinical response to the different ADs, results that could eventually be applied directly to clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some users react differently to the same antidepressant [19] while different antidepressants produce different effects [20].”
From ‘In my life antidepressants have been…’: a qualitative analysis of users’ diverse experiences with antidepressants (2016) · cites this paper as [20]
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“(Hamilton, 1960).”
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923 · cited 1×
“To determine if one drug acts faster than the other and/ or placebo in reducing the overall severity or specific symptomatic behaviors during this 2-week treatment period, the linear mixed model (Laird and Ware, 1982) was used to model the longitudinal change in each construct.”
MethodKupper, L. L., Hosmer, D. W., & Lemeshow, S. (1990) · Journal of the American Statistical Association · doi:10.2307/2290035 · Cited by 7,599
A Diagnostic Interview: The Schedule for Affective Disorders and Schizophrenia
Endicott, J. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770310043002 · Cited by 5,684 · cited 2×
“…approach (Katz et al, 1984), doctor ratings included the Ham-D, CGI, Schedule for Affective Disorders, and SchizophreniaChange Version (SADS-C, Endicott and Spitzer, 1978), Global Assessment Scale (GAS, Endicott et al, 1976), Video Interview Behavioral Evaluation Scales (VIBES) (Katz and…”
MethodThe Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982 · cited 1×
“…Ham-D, CGI, Schedule for Affective Disorders, and SchizophreniaChange Version (SADS-C, Endicott and Spitzer, 1978), Global Assessment Scale (GAS, Endicott et al, 1976), Video Interview Behavioral Evaluation Scales (VIBES) (Katz and Itil, 1974); nurse ratings: the Affective Disorder Rating Scale…”
BackgroundAn inventory for assessing different kinds of hostility.
Buss, A. H., & Durkee, A. (1957) · Journal of Consulting Psychology · doi:10.1037/h0046900 · Cited by 2,575 · cited 2×
“…(Murphy et al, 1980), NIMH Mood Scale (Raskin et al, 1969), Global Ward Behavior Scale (Raskin et al, 1969); patient self-reports included the Symptoms Checklist (SCL-90; Derogatis et al, 1974); NIMH Mood Scale (Raskin et al, 1969); and the Buss–Durkee Hostility Inventory (Buss and Durkee, 1957).”
MethodWillner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832 · cited 1×
“This later behavioral effect of paroxetine may not be due to serotonin exclusively, but to sequential or direct interactions between serotonin and noradrenergic or even dopaminergic systems (Willner, 1997; Bonhomme and Esposito, 1998; Bourin et al, 2001).”
Background
Research works printed but not linked: 3
- Guy W (1976). Early clinical drug evaluation program (ECDEU). In: Assessment Manual of Psychopharmacology. Department of Health, Education and Welfare: Rockville MD.
- Murphy DL, Pickar D, Alterman JS (1980). Methods for the quantitative assessment of depressive and manic behavior. In: Burdock EJ, Sudilovsky A, Gershon S (eds) Quantitative Techniques for the Evaluation of the Behavior of Psychiatric Patients. Marcel-Decker: New York, 355–392.
- Spitzer RL, Williams JBW (1983). Instruction manual For the Structured Clinical Interview for DSM III (SCID), Revision. Biometrics Research Department, M.Y. State Psychiatric Institute: New York.
Cited by
Items 101–200 of 266
Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder
Papakostas, G. I., Petersen, T., Sklarsky, K. G., Nierenberg, A. A., Alpert, J. E., & Fava, M. (2006) · Psychiatry Research · doi:10.1016/j.psychres.2006.03.014 · Cited by 35
“A recent study suggests that the onset of clinical response in depression occurs earlier-on for several symptoms including depressed mood, psychomotor retardation and hostility in antidepressant than placebo-responders, and as early as the first two weeks (Katz et al., 2004).”
BackgroundTadić, A., Wagner, S., Gorbulev, S., Dahmen, N., Hiemke, C., Braus, D. F., & Lieb, K. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-16 · Cited by 33
“The occurrence of improvement of depressive symptoms in the early course of treatment has been identified as being highly predictive for final treatment outcome [15-18,22-25], corroborating the idea that early improvement (typically defined as a 20% reduction of depressive symptoms, measured with rating scales like th…”
BackgroundGardier, A. M., Guiard, B. P., Guilloux, J., Repérant, C., Coudoré, F., & David, D. J. P. (2009) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00640.x · Cited by 40
Farabaugh, A. H., Mischoulon, D., Fava, M., Wu, S. L., Mascarini, A., Tossani, E., & Alpert, J. E. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200503000-00004 · Cited by 36
“In accordance with Katz et al. (2004), the findings of the present study indicate that patients in the placebo arm showed no consistent early changes that were predictive of response.”
BackgroundResultInfluentialYuan, H., Zhu, X. L., Tang, W., Cai, Y., Shi, S., & Luo, Q. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.041 · Cited by 33
Early Prediction of Fluoxetine Response for Han Chinese Inpatients With Major Depressive Disorder
Lin, C., Lane, H., Chen, C., Juo, S. H., & Yen, C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318210856f · Cited by 32
Raskin, J., Xu, J. Y., & Kajdasz, D. K. (2007) · International Psychogeriatrics · doi:10.1017/s1041610207005649 · Cited by 33
Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date
Ragguett, R.-M., Rong, C., Kratiuk, K., & McIntyre, R. S. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1559295 · Cited by 30
“longer for optimal antidepressant relief which can prolong morbidity, suicide risk, and functional impairment [11].”
BackgroundBrühl, A. B., Jäncke, L., & Herwig, U. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2227-2 · Cited by 31
“The behavioral improvements observed after antidepressant treatment may depend upon adaptive and neuroplastic changes that occur in regions expressing neurotransmitter transporters after repeated administration of antidepressant drugs (Katz et al. 2004; Donnici et al. 2008).”
BackgroundWu, Y., He, H., Bertekap, R. L., Westphal, R. S., Lelas, S., Newton, A. E., Wallace, T. L., Taber, M. T., Davis, C. D., Macor, J. E., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.02.010 · Cited by 29
Witkin, J. M., Wallace, T. L., & Martin, W. J. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_186 · Cited by 31
Guo, Y., Xia, M., Ye, R., Bai, T., Wu, Y., Ji, Y., Yu, Y., Ji, G., Wang, K., He, Y., et al. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.03.012 · Cited by 28
Yoshimura, R., Umene‐Nakano, W., Suzuki, A., Ueda, N., Miyamoto, K., Ikenouchi, A., Hori, H., Otani, K., & Nakamura, J. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1043 · Cited by 28
Hatzenbuhler, N. T., Baudy, R. B., Evrard, D. A., Failli, A. A., Harrison, B. L., Lenicek, S., Mewshaw, R. E., Sabb, A. L., Shah, U. S., Sze, J. Y., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8007097 · Cited by 28
the EMC Study Group, Tadić, A., Gorbulev, S., Dahmen, N., Hiemke, C., Braus, D. F., Röschke, J., van Calker, D., Wachtlin, D., Kronfeld, K., et al. (2010) · Trials · doi:10.1186/1745-6215-11-21 · Cited by 29
“Katz and colleagues reported on a randomised controlled trial (RCT) in which patients were treated with the selelctive serotonin reuptake inhibitor paroxetine, the tricyclic antidepressant desipramine or placebo [20].”
BackgroundKeeping up with the clinical advances: depression
Ragguett, R.-M., Tamura, J. K., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852919001159 · Cited by 27
Rapid treatments for depression: Endocannabinoid system as a therapeutic target
Sharafi, A., Pakkhesal, S., Fakhari, A., Khajehnasiri, N., & Ahmadalipour, A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104635 · Cited by 31
Timing of Clinical Improvement and Symptom Resolution in the Treatment of Major Depressive Disorder
Papakostas, G. I., Crawford, C. M., Scalia, M. J., & Fava, M. (2007) · Neuropsychobiology · doi:10.1159/000115779 · Cited by 27
Vermeiden, M., Kamperman, A. M., Vulink, M. E., van den Broek, W. W., & Birkenhäger, T. K. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3765-1 · Cited by 26
“In contrast, several studies found evidence of early drug response occurring within the first 2 weeks of antidepressant treatment and that this early onset response may predict eventual treatment outcome (Katz et al. 2004; Henkel et al. 2009; Szegedi et al. 2003; Brannan et al. 2005; Entsuah et al. 1998; Nagayama et a…”
ResultHara, H., Suzuki, A., Kunugi, A., Tajima, Y., Yamada, R. X., & Kimura, H. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173289 · Cited by 26
“Currently prescribed monoaminergic antidepressants exhibit a delayed onset of action, usually requiring several weeks or months before showing an adequate therapeutic response (Katz et al., 2004).”
BackgroundKamp, C. B., Petersen, J. J., Faltermeier, P., Juul, S., Siddiqui, F., Barbateskovic, M., Kristensen, A. T., Moncrieff, J., Horowitz, M. A., Hengartner, M. P., et al. (2024) · BMJ Mental Health · doi:10.1136/bmjment-2023-300730 · Cited by 29
Evrard, D. A., Zhou, P. H., Yi, S. Y., Zhou, D., Smith, D. L., Sullivan, K. M., Hornby, G. A., Schechter, L. E., Andree, T. H., & Mewshaw, R. E. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.12.064 · Cited by 24
Witkin, J. M., Cerne, R., Wakulchik, M., S., J., Gleason, S. D., Jones, T. M., Li, G., Arnold, L. A., Li, J., Schkeryantz, J. M., et al. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.04.009 · Cited by 25
“These agents are acutely active unlike the SSRI anti-anxiety drugs (Katz et al., 2004).”
BackgroundKatz, M. M., Houston, J., Brannan, S., Bowden, C. L., Berman, N., Swann, A. C., & Frazer, A. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004407 · Cited by 22
“…constructs derived from the original MV have also been demonstrated to be sensitive to early behavioural change in a recently completed placebo-controlled inpatient study which examined the onset, timing and nature of the behavioural actions of paroxetine and desipramine (Katz et al., 2004).”
BackgroundMethodResultInfluentialSelf-citationPérez de la Mora, M., Borroto-Escuela, D. O., Crespo-Ramírez, M., Rejón-Orantes, J. D. C., Palacios-Lagunas, D. A., Martínez-Mata, M. K., Sánchez-Luna, D., Tesoro-Cruz, E., & Fuxe, K. (2022) · Cells · doi:10.3390/cells11111826 · Cited by 21
Yang, R., Wang, L., Jin, K., Cao, S., Wu, C., Guo, J., Chen, J., Tang, H., & Tang, M. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.876152 · Cited by 26
Pilc, A., Machaczka, A., Kawalec, P., Smith, J. L., & Witkin, J. M. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2111415 · Cited by 21
Prins, J., Westphal, K. G. C., Korte-Bouws, G. A. H., Quinton, M. S., Schreiber, R., Olivier, B., & Korte, S. M. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.10.001 · Cited by 21
Xiao, L., Zhu, X., Gillespie, A. L., Feng, Y., Zhou, J., Chen, X., Gao, Y., Wang, X., Ma, X., Gao, C., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291719004069 · Cited by 21
“⩾20% reduction in depressive symptoms after 2 weeks of treatment) predicts later clinical remission and symptom reduction at weeks 6, 8 and 10 with high sensitivity (Katz et al., 2004; Szegedi et al., 2003; Szegedi et al., 2009; Wagner et al., 2017).”
BackgroundMooney, J. J., SAMSON, J. A., Hennen, J. A., Pappalardo, K. M., McHale, N. L., Alpert, J. E., Koutsos, M., & Schildkraut, J. J. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.07.009 · Cited by 21
“This time delay between the acute or short-term neuropharmacological effects of these antidepressants and their clinical antidepressant effects has posed a major problem in neuropsychopharmacology since the early 1960s (Katz et al., 2004).”
BackgroundYoshida, K., Roberts, R., Suzuki, T., Lebowitz, B. D., Reeves, S., Howard, R. J., Abe, T., Mimura, M., & Uchida, H. (2017) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2017.01.016 · Cited by 24
“Such associations have also been previously identified in relation to antidepressant treatment.(17,31,32) Because there has been no prior report of the degree of change that should be used to define early improvement with antipsychotic treatment in BPSD, we tested consecutive cut-off points to explore the optimum thre…”
ResultElectroconvulsive therapy regulates emotional memory bias of depressed patients
Bai, T., Xie, W., Wei, Q., Chen, Y., Mu, J., Tian, Y., & Wang, K. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.07.069 · Cited by 21
Zhu, J., Cai, H., Yuan, Y., Yue, Y., Jiang, D., Chen, C., Zhang, W., Zhuo, C., & Yu, Y. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-018-9845-9 · Cited by 20
Albert, U., Lamba, P., & Stahl, S. M. (2021) · CNS Spectrums · doi:10.1017/s1092852921000304 · Cited by 19
Huang, S., Zhang, X., Wang, Y., Pan, J., Cui, H., Fang, S.-P., Wu, W., Zheng, J., Li, D.-J., & Bai, G. (2014) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-014-1343-0 · Cited by 19
Review: The importance of early symptom relief in antidepressant treatment: focus on agomelatine
Lam, R. W. M. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810372979 · Cited by 20
“Some investigators have proposed that specific pharmacological effects of antidepressants may differentially affect the onset of neurobehavioral changes, with serotonergic effects taking longer than noradrenergic effects (Katz et al., 2004, 2006).”
BackgroundBae, K., Kim, S., Kim, J. M., Shin, I., Yoon, J., Jung, S.-W., Lee, M., Yim, H. W., & Jun, T. (2011) · Psychiatry Investigation · doi:10.4306/pi.2011.8.3.234 · Cited by 23
Carratalá‐Ros, C., López‐Cruz, L., Martínez-Verdú, A., Olivares-García, R., Salamone, J. D., & Correa, M. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.700182 · Cited by 19
Kang, S. Y., Park, E., Park, W.-K., Kim, H. J., Choi, G., Jung, M. E., Seo, H. J., Kim, M. J., Pae, A. N., Kim, J., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.06.037 · Cited by 18
Amphetamines abuse and depression: Focus on TRPC channels
Fu, Y.-P., & Wang, Y. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114391 · Cited by 17
Craving and addictive potential of esketamine as side effects?
Orsolini, L., Salvi, V., & Volpe, U. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2071422 · Cited by 18
“symptomatology improvement [5], RAAD have the potential”
Clinical pharmacological innovation in the treatment of depression
Witkin, J. M., Golani, L. K., & Smith, J. L. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2198703 · Cited by 17
Feasibility of a slower lamotrigine titration schedule for bipolar depression: a naturalistic study
Joe, S. H., Chang, J. S., Won, S., Rim, H.-D., Ha, T. H., & Ha, K. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832775fe · Cited by 18
“to lamotrigine may also provide useful information for practical and effective clinical decisions (Katz et al., 2004).”
BackgroundHelmreich, I., Wagner, S., König, J., Kohnen, R., Szegedi, A., Hiemke, C., & Tadić, A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.12.043 · Cited by 18
Furukawa, T. A., Kato, T., Shinagawa, Y., Miki, K., Fujita, H., Tsujino, N., Kondo, M., Inagaki, M., & Yamada, M. (2018) · Psychological Medicine · doi:10.1017/s0033291718003331 · Cited by 17
“Observations early in the course of the treatment can also be informative: early improvement within 1–3 weeks of treatment has been found repeatedly to be a predictor of good outcomes (Katz et al., 2004; Henkel et al., 2009; Szegedi et al., 2009; Tadic et al., 2010).”
BackgroundResultCzopek, A., Kołaczkowski, M., Bucki, A., Byrtus, H., Pawłowski, M., Siwek, A., Bojarski, A. J., Bednarski, M., Wróbel‐Biedrawa, D., & Wesołowska, A. (2013) · Archiv der Pharmazie · doi:10.1002/ardp.201200378 · Cited by 17
Averill, I. R. E., Crowe, M., Frampton, C. M., Beaglehole, B., Lacey, C. J., Jordan, J., Wilson, L., Douglas, K. M., & Porter, R. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867417753549 · Cited by 17
Ketamine: Leading us into the future for development of antidepressants
Carreno, F. R., Lodge, D. J., & Frazer, A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112532 · Cited by 16
“The major drawbacks associated with such drugs are that (1) optimal, not necessarily initial, beneficial effects can be delayed for weeks if not months [5, 6]; (2) response and remission rates are low, 50% and 30% respectively [4], such that the effect sizes for these drugs are in the modest range of 0.”
BackgroundSelf-citationInvolvement of muscarinic receptor mechanisms in antidepressant drug action
Witkin, J. M., Smith, J. L., Golani, L. K., Brooks, E. A., & Martin, A. E. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.03.003 · Cited by 18
Serres, F., Millan, M. J., & Sharp, T. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000733 · Cited by 17
“Currently available antidepressant drugs require administration over several weeks to produce a full therapeutic effect, implicating neuroadaptive changes in their mechanism of action (Katz et al. 2004; Millan, 2006 ; Papakostas et al. 2006).”
BackgroundFarabaugh, A. H., Sonawalla, S. B., Johnson, D. P., Witte, J. M., Papakostas, G. I., Goodness, T. M., Clain, A. J., Baer, L., Mischoulon, D., D, M. F. M., et al. (2010) · Annals of Clinical Psychiatry · doi:10.1177/104012371002200305 · Cited by 16
Kolasa, M., Kuśmider, M., Solich, J., Faron‐Górecka, A., Krawczyk, M. J., KUŁAKOWSKI, K., & Dziedzicka‐Wasylewska, M. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2714-0 · Cited by 18
“However, some reports indicate that treatment with selective serotonin reuptake inhibitors (SSRIs) is associated with symptomatic improvement by the end of the first week or even as quickly as within the first 3 days of treatment (Taylor et al. 2006; Mitchell 2006; Katz et al. 2004).”
Funaki, K., Nakajima, S., Suzuki, T., Mimura, M., & Uchida, H. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.710 · Cited by 16
The missing link between clinical endpoints and drug targets in depression
Pasqua, O. E. D., Santen, G. W. E., & Danhof, M. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.12.004 · Cited by 18
Replication of distinct trajectories of antidepressant response to intravenous ketamine
O’Brien, B., Lee, J., Kim, S., Nandra, G. S., Pannu, P., Swann, A. C., Murphy, N., Tamman, A. J. F., Amarneh, D. Y., Lijffijt, M., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.10.031 · Cited by 16
Dang, K., Ritvo, P., Katz, J. D., Gratzer, D., Knyahnytska, Y., Ortiz, A., Walters, C., Attia, M., Gonzalez‐Torres, C., Lustig, A., et al. (2023) · Interactive Journal of Medical Research · doi:10.2196/46419 · Cited by 15
“This finding is consistent with previous evidence demonstrating the predictive value of early changes for later outcomes [96], with most studies focusing on early psychological gains [45,97,98] and fewer on early behavioral gains [47,48].”
BackgroundResultFerber, S. G., Weller, A., Yadid, G., & Friedman, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041867 · Cited by 14
New Approaches to the Pharmacological Management of Major Depressive Disorder
Witkin, J. M., & Li, X. (2009) · Advances in pharmacology · doi:10.1016/s1054-3589(08)57009-8 · Cited by 15
Delayed effects of antidepressant drugs in rats
Kuśmider, M., Faron‐Górecka, A., & Dziedzicka‐Wasylewska, M. (2006) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3280116ea2 · Cited by 14
“These results might be regarded as an analogy to the recent clinical data reported by Katz et al. (2004), who have shown early drug-specific behavioral changes in depressive patients, which were highly predictive of ultimate clinical response.”
BackgroundResultBitran, S., Farabaugh, A. H., Ameral, V., LaRocca, R. A., Clain, A. J., D, M. F. M., & Mischoulon, D. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328343ba08 · Cited by 13
“…eventual response or remission; examples include the HAM-D scaledepressed mood item (Bech, 2001; Katz et al., 2004, 2009), motor retardation (Katz et al., 2004, 2009), anxiety (Katz et al., 2004, 2009; Farabaugh et al., 2005, 2010), cognition and psychomotor changes (Tollefson and Holman,…”
BackgroundInfluentialMalatyńska, E., Pinhasov, A., Creighton, C. J., Crooke, J. J., Reitz, A. B., Brenneman, D. E., & Lubomirski, M. S. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.05.004 · Cited by 13
“Expectations of an early antidepressant effect from responder groups also changed the timing of data collection in clinical trials from weekly to 3 day or even more frequent intervals (for in-depth discussion of these approaches see reviews by Katz et al., 2002, 2004a).”
BackgroundMethodResultJakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1311-5 · Cited by 14
Meiering, M. S., Weigner, D., Gärtner, M., Schäfer, T., & Grimm, S. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.10.062 · Cited by 13
Boessen, R., Knol, M. J., Groenwold, R. H. H., Grobbee, D. E., & Roes, K. C. B. (2012) · Clinical Trials · doi:10.1177/1740774512456454 · Cited by 12
Katz, M. M., Bowden, C. L., Berman, N., & Frazer, A. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000246220.04422.de · Cited by 12
“For future drug development, they must also note that the AD which induces the quickest response is the selective noradrenergic, not the SSRI or tricyclic drug.(5) Regarding methodological implications, profiling of changes in behavior induced by drugs during the time course of successful treatment has been seriously…”
BackgroundMethodSelf-citationShort-Term Duloxetine Administration Affects Neural Correlates of Mood-Congruent Memory
Tendolkar, I., van Wingen, G. A., Urner, M., Verkes, R. J., & Fernández, G. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.114 · Cited by 12
“In a setting more informative for treatment (Katz et al, 2004), we applied a short-term administration of duloxetine (for 2 weeks) in a randomized, double-blind, placebo-controlled, cross-over design.”
MethodThe why, when, where, how, and so what of so-called rapidly acting antidepressants
Schatzberg, A. F., & Mathew, S. J. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01647-8 · Cited by 11
“Katz and colleagues [36] noted in a comparison study that desipramine produced rapid effects on psychomotor retardation, paroxetine rapidly reduced anxiety, but placebo did not produce a consistent pattern of improvement.”
ResultWang, S., Chen, Y., Liu, X., Xu, X., Liu, X., Liu, B., & Zhang, G. (2013) · Archiv der Pharmazie · doi:10.1002/ardp.201300238 · Cited by 11
Rethinking the medication management of major depression
Mann, J. J., & Rizk, M. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2190886 · Cited by 10
Post-Myocardial Infarction Depression
Rousseau, G., Bah, T. M., & Godbout, R. (2012) · InTech eBooks · doi:10.5772/33408 · Cited by 13
Guo, J. P., Zhou, D., Grimm, S. W., & Bui, K. (2014) · Xenobiotica · doi:10.3109/00498254.2014.966175 · Cited by 10
“In addition, the onset of therapeutic action for these standard antidepressant treatments is so slow that several weeks of continuous administration is required to achieve clinically meaningful changes in symptoms (Katz et al., 2004; Thompson, 2002).”
BackgroundBowman, M. A., Mitchell, N. C., Owens, W. A., Horton, R. E., Koek, W., & Daws, L. C. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173285 · Cited by 11
Topic, B., Kröger, I., Vildirasova, P. G., & Huston, J. P. (2012) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2012.09.007 · Cited by 10
Efficacy of ketamine versus esketamine in the treatment of perioperative depression: A review
Wen, W., Zhao, W., Xia, X., Duan, X., Zhang, L., Lin, D., Qi, Z., Wang, S., Gao, M., Liu, C., et al. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173773 · Cited by 9
Altın, M., Harada, E., Schacht, A., Berggren, L., Walker, D. J., & Dueñas, H. (2014) · Open Journal of Depression · doi:10.4236/ojd.2014.33015 · Cited by 9
Yuan, H., Zhu, X. L., Luo, Q., Halim, A., Halim, M., Yao, H., Cai, Y., & Shi, S. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s196533 · Cited by 11
Li, B., Suemaru, K., Kitamura, Y., Cui, R., Gomita, Y., & Araki, H. (2007) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.127.735 · Cited by 9
Dou, Y., Yang, X., Du, Y., Cui, W., Luo, Y., Wei, J., Zhao, L., Cai, X., Ma, X., & Lin, Y. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.152031 · Cited by 8
Tian, S., Wang, Q., Zhang, S., Chen, Z., Dai, Z., Zhang, W., Yao, Z., & Lü, Q. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.08.096 · Cited by 7
Efficacy of different doses of ketamine as a bolus in major depressive disorder.
Kheirkhah, F., Tayyebi, G., Rabiee, S. M., Moghadamnia, A. A., & Bijani, A. (2018) · PubMed Central · doi:10.22088/cjim.9.3.220 · Cited by 7
“Yet, only half of individuals with major depressive episodes respond to the traditional antidepressants, that full clinical benefit of these is only achieved following weeks to months of treatment (7, 8).”
BackgroundSnippe, E., Elmer, T., Ceulemans, E., Smit, A. C., Lutz, W., & Helmich, M. A. (2024) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000890 · Cited by 8
Sarris, J. J., Nierenberg, A. A., Schweitzer, I., Alpert, J. E., Rosenbaum, J. F., Iovieno, N., Covino, J. M., D, M. F. M., & Mischoulon, D. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31829cc3af · Cited by 7
‘Delay’ hypothesis of onset of antidepressant action
Katz, M. M., Frazer, A., & Bowden, C. L. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.188.6.586-a · Cited by 7
Self-citationIs peripartum magnesium sulfate associated with a reduction in postpartum depressive symptoms?
Miller, E. S., Sakowicz, A., Roy, A., Wang, A., Yang, A., Ciolino, J. D., Grobman, W. A., Wisner, K. L., & Yee, L. M. (2021) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2021.100407 · Cited by 6
Depression and Drugs – The Neurobehavioral Structure of a Psychological Storm
Katz, M. M. (2014) · PSYCH up2date · doi:10.1055/s-0033-1337066 · Cited by 6
Self-citationChaudhary, P., Shah, P., & Mehta, P. (2022) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_231_21 · Cited by 5
Efficacy comparison of duloxetine and SSRIs at doses approved in Japan
Harada, E., Schacht, A., Koyama, T., Marangell, L. B., Tsuji, T., & Escobar, R. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s72642 · Cited by 5
“This is consistent with previous reports by Mallinckrodt et al 16 and Martinez et al. 24 Furthermore, Katz et al 25 reported that desipramine (a norepinephrine reuptake inhibitor) demonstrated better efficacy than paroxetine (an SSRI) on psychomotor retardation symptoms.”
Takahashi, H., Sueki, A., Suzuki, E., & Ishigooka, J. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s103432 · Cited by 5
Is the Ultimate Treatment Response Predictable with Early Response in Major Depressive Episode?
Ciftci, A., Ulaş, H., Topuzoǧlu, A., & Tunca, Z. (2015) · Nöro Psikiyatri Arşivi · doi:10.5152/npa.2015.10141 · Cited by 5
“(11) in 2004 with patients taking paroxetine, which is SSRI, and desipramine, which is a norepinephrine reuptake inhibitor and placebo, it was reported that with both drugs, the response observed in the first two weeks was correlated with treatment response observed at the end of six weeks.”
Inoue, T., Fujimoto, S., Marumoto, T., Kitagawa, T., Ishida, K., Nakajima, T., Moriguchi, Y., Fujikawa, K., & Watanabe, K. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s340309 · Cited by 5
“response is obtained in a patient receiving antidepressant therapy, physicians are typically advised to consider alternatives to the patient’s treatment regimen to obviate unnecessary suffering and exposure to a high risk of suicide.(5,6) The Japanese Society of Mood Disorders recommends that patients be switched to a…”
BackgroundPrediction of Response Within the First 3 Days to Treatment With Paroxetine for Depression
Inagaki, T., Furuya, M., Kawamukai, T., Okazaki, S., YASUDA, H., Hayashida, M., Miyaoka, T., Nishida, A., & Horiguchi, J. (2008) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v10n0207 · Cited by 5
“The earliest improvement in paroxetine responders was anxiety, and depressed mood and cognitive impairment improved somewhat later.(10) In this study, the reduction rate of the core subscale decreased significantly earlier than that of the anxiety/somatization subscale on the third day.”
BackgroundProteomic patterns associated with ketamine response in major depressive disorders
Zhou, N., Shi, X., Wang, R., Wang, C., Lan, X., Liu, G., Li, W., Zhou, Y., & Ning, Y. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-024-09981-3 · Cited by 4
Çorumlu, E. P., Aydın, O. Ö., Aydın, E. G. G., & Ulupınar, E. (2015) · Anatomy (International Journal of Experimental and Clinical Anatomy) · doi:10.2399/ana.15.027 · Cited by 6
“The full clinical benefits of conventional antidepressants take weeks to months start working.([4]) This time lag to therapeutic efficacy is a serious problem especially in considering the high suicide risk associated with MDD.”
Liu, W., Heij, J., Liu, S., Liebrand, L. C., Caan, M. W. A., van der Zwaag, W., Veltman, D. J., Lü, L., Aghajani, M., & van Wingen, G. A. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.07.014 · Cited by 4
“However, these medications typically require several weeks to take effect (Katz et al., 2004), and about 50%-60% of patients fail to attain a sufficient response after undergoing antidepressant treatment (Fava, 2003).”
BackgroundA video method for the evaluation of antidepressant clinical and behavioural actions
Katz, M. M., Houston, J., Brannan, S. K., Tekell, J. L., Berman, N., Bowden, C. L., & Frazer, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005778 · Cited by 4
“Clinical response at the end of the pre-treatment period was measured using the HAMD and by a ‘multivantaged’ set of behavioural techniques (Katz et al., 2004a).”
BackgroundMethodResultInfluentialSelf-citationLeung, S. M. (2021) · Brain and Behavior · doi:10.1002/brb3.2311 · Cited by 4
“The association of positive pattern of treatment result with patients’ background characteristics in patients using agomelatine Accordingtosomestudies,theaveragetimeforonsetofantidepres-sant action was 13 days (Katz et al., 2004; Stassen et al., 1993).”
Common Substrates of Dysphoria in Stimulant Drug Abuse and Primary Depression: Therapeutic Targets
Baicy, K., Bearden, C. E., Monterosso, J. R., Brody, A. L., Isaacson, A. J., & London, E. D. (2005) · International review of neurobiology · doi:10.1016/s0074-7742(04)65005-7 · Cited by 4
Wu, Y., He, H., Gao, Q., Wu, D., Bertekap, R. L., Westphal, R. S., Lelas, S., Newton, A. E., Wallace, T. L., Taber, M. T., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.01.036 · Cited by 4
Kirchheiner, J., Seeringer, A., Viviani, R., & Hodgkinson, S. C. (2010) · Advances in biological psychiatry · doi:10.1159/000317295 · Cited by 4
Differential-Reinforcement-of-Low-Rate Behavior in Rodents as a Screen for Antidepressant Efficacy
Lueptow, L. M., & O’Donnell, J. M. (2011) · Neuromethods · doi:10.1007/978-1-61779-313-4_18 · Cited by 3
Metadata
- Authors
- Katz, M. M., Tekell, J. L., Bowden, C. L., Brannan, S., Houston, J. P., Berman, N., & Frazer, A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Dallas VA Medical Center (US)
- Harbor–UCLA Medical Center (US)
- Corresponding author
- Frazer, Alan
- ORCID
- Frazer, Alan
- Venue
- Neuropsychopharmacology
- Published
- 2003-11-19
- Volume
- 29
- Issue
- 3
- Pages
- 566-579
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2319982487
- Cited by
- 252
- References
- 72
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 7 · 2023: 10 · 2022: 9 · 2021: 11 · 2020: 11 · 2019: 8 · 2018: 11 · 2017: 8 · 2016: 14 · 2015: 13 · 2014: 10 · 2013: 20 · 2012: 7
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Texas Health Science Center at San Antonio
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- antidepressant onset of action, depression, paroxetine, desipramine, selective serotonin reuptake inhibitors, noradrenergic reuptake inhibitors, placebo response, motor retardation, depressive mood, anxiety, treatment response prediction
- MeSH terms
- Adult, Affect, Aged, Analysis of Variance, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Desipramine, Double-Blind Method, Female, Humans, Male, Middle Aged, Motor Activity, Time Factors, Placebo Effect, Chi-Square Distribution, Logistic Models, Paroxetine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.